Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.

Authors

Koen Van Besien
Lizamarie Bachier-Rodriguez
Michael Satlin
Maxwell A Brown
Usama Gergis MD, MBA, Lehigh Valley Health NetworkFollow
Danielle Guarneri
Jingmei Hsu
Adrienne A Phillips
Sebastian A Mayer
Amrita D Singh
Rosemary Soave
Adriana Rossi
Catherine B Small
Thomas J Walsh
Hanna Rennert
Tsiporah B Shore

Publication/Presentation Date

7-1-2019

Abstract

Epstein-Barr virus (EBV) reactivation and post-transplant lymphoproliferative disorders (PTLD) are common and potentially fatal complications after allogeneic transplantation with mismatched donors and T-cell depletion. Haplo-cord transplantation combines a mismatched UCB graft with third-party cells. Conditioning involves thymoglobulin. EBV reactivation and PTLD were common in initial patients. As of March 2017, we administered a prophylactic dose of rituximab 375 mg/m

Volume

60

Issue

7

First Page

1693

Last Page

1696

ISSN

1029-2403

Published In/Presented At

Van Besien, K., Bachier-Rodriguez, L., Satlin, M., Brown, M. A., Gergis, U., Guarneri, D., Hsu, J., Phillips, A. A., Mayer, S. A., Singh, A. D., Soave, R., Rossi, A., Small, C. B., Walsh, T. J., Rennert, H., & Shore, T. B. (2019). Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. Leukemia & lymphoma, 60(7), 1693–1696. https://doi.org/10.1080/10428194.2018.1543877

Disciplines

Medicine and Health Sciences

PubMedID

30741059

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Lehigh Valley Topper Cancer Institute

Document Type

Article